<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01086579</url>
  </required_header>
  <id_info>
    <org_study_id>BELLO</org_study_id>
    <nct_id>NCT01086579</nct_id>
  </id_info>
  <brief_title>Balloon Elution and Late Loss Optimization (BELLO) Study</brief_title>
  <acronym>BELLO</acronym>
  <official_title>Balloon Elution and Late Loss Optimization (BELLO) Study: A Multicentre Randomized Study of the IN.PACT Falcon™ Paclitaxel Drug-eluting Balloon to Reduce Restenosis in Small Coronary Vessels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective multicentre randomized (1:1) investigator initiated study, in which consecutive&#xD;
      patients undergoing percutaneous revascularization of small coronary vessels will be assigned&#xD;
      to one of the two study arms:&#xD;
&#xD;
        1. Treatment Arm: IN.PACT Falcon™ paclitaxel drug-eluting balloon (DEB) dilatation and&#xD;
           provisional spot bare-metal stenting (BMS).&#xD;
&#xD;
        2. Control Arm: paclitaxel-eluting stent (PES) implantation as per standard practice.&#xD;
&#xD;
      Eligible subjects with coronary artery disease in a small vessel (reference diameter&lt;2.8mm)&#xD;
      will be consecutively screened and enrolled based on the inclusion and exclusion criteria&#xD;
&#xD;
      The objective of the study is to assess the non-inferiority of the DEB to the PES as regards&#xD;
      to primary endpoint of mean late lumen loss (LLL) at 6 months, defined as the difference&#xD;
      between postprocedural minimum luminal (MLD) diameter and follow-up MLD, as assessed by&#xD;
      quantitative coronary angiography and is based on the following assumptions:&#xD;
&#xD;
        1. The means of LLL in the 2 groups are precisely equal&#xD;
&#xD;
        2. A standard deviation in LLL of 0.5mm in both groups as demonstrated in the ISAR-SMART 3&#xD;
           and PEPCAD II trials&#xD;
&#xD;
        3. A non-inferiority margin of 0.25mm between groups is clinically unimportant&#xD;
&#xD;
      Based on these assumptions:&#xD;
&#xD;
        1. Null hypothesis (N0): mean LLL in DEB group is ≥0.25mm than that in the PES group (i.e.&#xD;
           PES is superior to DEB)&#xD;
&#xD;
        2. Alternative hypothesis 1 (H1): mean LLL between DEB and PES is &lt;0.25mm (i.e. DEB is&#xD;
           non-inferior to PES)&#xD;
&#xD;
        3. Alternative hypothesis 2 (H2): mean LLL between DEB and PES &lt;0 (i.e. DEB is superior to&#xD;
           PES) Based on the above calculations, a sample size of 77 patients will be required in&#xD;
           each group to show non-inferiority of DEB vs. PES with an α error of 0.025 (one-sided Z&#xD;
           test) and a power of 80%. To account for a 20% rate of withdrawal, lost to follow-up or&#xD;
           not presenting for follow-up angiography, a total of 182 patients (91 in each group)&#xD;
           will be randomized.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late Lumen Loss (LLL) at 6 months follow-up defined as the difference between postprocedural minimum luminal diameter and follow-up minimum luminal diameter, as assessed by quantitative coronary angiography</measure>
    <time_frame>6 Month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Success: ability of the Investigational Device to be delivered, dilate, and be retrieved from the target lesion.</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success: defined as Device Success without the occurrence of Major Adverse Cardiac Events (MACE) during the index hospitalization</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE rate through 30 days, 6 months,1, 2, 3 years post index procedure</measure>
    <time_frame>30 days, 6 months,1, 2, 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR) at 6 months,1, 2, 3 years post index procedure</measure>
    <time_frame>6 months,1, 2, 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR) at 6 months,1, 2, 3 years post index procedure</measure>
    <time_frame>6 months,1, 2, 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure (TVF), defined as cardiac death, Myocardial Infarction (MI) or TVR at 1 year</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary Restenosis rate at 6 months follow-up</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">182</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Treatment Arm (IN.PACT Falcon Drug Eluting Balloon)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IN.PACT Falcon™ paclitaxel drug-eluting balloon (DEB) dilatation and provisional spot bare metal stenting (Bare Metal Stent).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm PES</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control Arm: paclitaxel-eluting stent (PES) implantation as per standard practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IN.PACT Falcon paclitaxel eluting balloon (Drug eluting balloon)</intervention_name>
    <description>Coronary Artery Bypass Graft (CABG)</description>
    <arm_group_label>Treatment Arm (IN.PACT Falcon Drug Eluting Balloon)</arm_group_label>
    <other_name>IN.PACT Falcon paclitaxel eluting balloon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Taxus (Paclitaxel eluting stent)</intervention_name>
    <description>Percutaneous transluminal coronary angioplasty (PTCA) with stent</description>
    <arm_group_label>Control Arm PES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years.&#xD;
&#xD;
          -  Patient providing written informed consent.&#xD;
&#xD;
          -  Patients with stable angina pectoris (Canadian Cardiovascular Society [CCS] 1, 2 3) or&#xD;
             unstable angina pectoris with documented ischemia (CCS 4, Braunwald Class IB-C, IIB-C&#xD;
             or IIIB-C), or patients with documented silent ischemia.&#xD;
&#xD;
          -  Patients who are eligible for coronary revascularization (angioplasty and/or CABG).&#xD;
&#xD;
          -  Female patients with child bearing potential must have a negative pregnancy test&#xD;
             within one week before treatment and must use adequate contraception.&#xD;
&#xD;
        Angiographic Inclusion Criteria:&#xD;
&#xD;
          -  Native coronary artery.&#xD;
&#xD;
          -  De novo lesion.&#xD;
&#xD;
          -  Reference vessel diameter &lt; 2.8mm by visual estimate.&#xD;
&#xD;
          -  Target lesion with a visually estimated stenosis &gt;50%.&#xD;
&#xD;
          -  Target lesion length &lt; 25mm by visual estimate.&#xD;
&#xD;
          -  A maximum of 2 epicardial vessels requiring revascularization.&#xD;
&#xD;
          -  A maximum of 2 target lesions can be included (In the case of treatment of more than&#xD;
             one lesion, the treatment selected will remain the same).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unable to give informed consent.&#xD;
&#xD;
          -  Patients enrolled in another study with any investigational drug or device within the&#xD;
             past 30 days.&#xD;
&#xD;
          -  Patients scheduled for a major surgical intervention within 6 months of enrolment in&#xD;
             the study.&#xD;
&#xD;
          -  Patients with acute (&lt; 24h) or recent (≤ 48 hours) myocardial infarction.&#xD;
&#xD;
          -  Patients with a contraindication to an emergency coronary bypass surgery.&#xD;
&#xD;
          -  Any individual who may refuse a blood transfusion.&#xD;
&#xD;
          -  Patients with serum creatinine &gt;2.0mg/dL or &gt;180umol/L.&#xD;
&#xD;
          -  Patients with severe congestive heart failure.&#xD;
&#xD;
          -  Patients who had a cerebral stroke &lt;6 months prior to the Index Procedure.&#xD;
&#xD;
          -  EF (Ejection Fraction) &lt; 30%.&#xD;
&#xD;
          -  Patients with any known allergy, hypersensitivity or intolerance to acetylsalicylic&#xD;
             acid (ASA), Clopidogrel or Ticlopidine, Paclitaxel.&#xD;
&#xD;
          -  Any known allergy to contrast medium that cannot be pre-treated.&#xD;
&#xD;
        Angiographic exclusion criteria:&#xD;
&#xD;
          -  &gt;2 epicardial vessels requiring revascularization.&#xD;
&#xD;
          -  Target lesion distance from the ostium of left anterior descending coronary artery&#xD;
             (LAD)/left circumflex coronary artery (LCX)/right coronary artery (RCA) is &lt; 5 mm.&#xD;
&#xD;
          -  Target lesion is located in either a venous or arterial graft.&#xD;
&#xD;
          -  Target vessel contains a previously implanted stent.&#xD;
&#xD;
          -  Angiographic evidence of thrombus at the target site.&#xD;
&#xD;
          -  Chronic total occlusions.&#xD;
&#xD;
          -  Restenotic lesions.&#xD;
&#xD;
          -  Bifurcation lesions which the operator decides a 2-stent technique as&#xD;
             intention-to-treat is required OR bifurcations with side branches ≥ 2.5mm.&#xD;
&#xD;
          -  Failure to successfully treat non-target lesions within the target vessel (non-target&#xD;
             lesions must be treated prior the target lesion).&#xD;
&#xD;
          -  Greater than 2 non-target lesions treated during the index procedure.&#xD;
&#xD;
          -  Previous Percutaneous Coronary Intervention (PCI) within the last 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Colombo, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Fondazione Centro S.Raffaele del Monte Tabor</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Corrado Tamburino, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Presidio Ospedaliero Ferrarotto di Catania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrizia Presbitero, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas di Rozzano (MI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alberta Pangrazi, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Ospedali Riuniti Umberto I-G.M.Lancisi-G.Salesi di Ancona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Violini, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera San Camillo Forlanini di Roma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesca Buffoli, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale &quot;C.Poma&quot; di Mantova</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maurizio Tespili, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera &quot;Bolognini&quot; di Seriate</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fausto Castriota, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Citta' di Lecce Hospital di Lecce</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alberto Cremonesi, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Villa Maria Cecilia Hospital di Cotignola</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Micari, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Villa Maria Eleonora Hospital di Palermo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfredo Marchese, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Casa di Cura &quot;AntheaHospital&quot; di Bari</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabrizio Tomai, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>European Hospital di Roma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Massimo Margheri, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale S.Maria delle Croci AUSL di Ravenna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alberto Menozzi, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero-Universitaria di Parma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Irccs Fondazione Centro S.Raffaele Del Monte Tabor</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://content.onlinejacc.org/article.aspx?articleid=1389701</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>March 11, 2010</study_first_submitted>
  <study_first_submitted_qc>March 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2010</study_first_posted>
  <last_update_submitted>August 13, 2013</last_update_submitted>
  <last_update_submitted_qc>August 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>paclitaxel PTCA drug-eluting balloon</keyword>
  <keyword>provisional spot stenting</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>Late Lumen Loss</keyword>
  <keyword>Minimal lumen diameter</keyword>
  <keyword>coronary artery disease in a small vessel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

